EP Patent

EP1430895A1 — Novel substituted benzimidazole dosage forms and method of using same

Assigned to University of Missouri Columbia · Expires 2004-06-23 · 22y expired

What this patent protects

The invention concerns a solid pharmaceutical dosage form capable of direct oral administration to a subject comprising at least one proton pump inhibitor in an amount of about 2 mg to about 300 mg; at least one buffering agent; and optionally one or more pharmaceutically accepta…

USPTO Abstract

The invention concerns a solid pharmaceutical dosage form capable of direct oral administration to a subject comprising at least one proton pump inhibitor in an amount of about 2 mg to about 300 mg; at least one buffering agent; and optionally one or more pharmaceutically acceptable excipients; and the use of such a dosage form in the manufacture of a medicament for treating a gastrointestinal disorder in a subject in need thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP1430895A1
Jurisdiction
EP
Classification
—
Expires
2004-06-23
Drug substance claim
No
Drug product claim
No
Assignee
University of Missouri Columbia
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.